|
1. |
ReviewNeuropsychological Effects of Antiepileptic DrugsA Current Perspective |
|
Clinical Neuropharmacology,
Volume 16,
Issue 6,
1993,
Page 471-484
Martha Nichols,
Kimford Meador,
David Loring,
Preview
|
PDF (891KB)
|
|
摘要:
Summary: Epilepsy has widespread direct and indirect effects on the patient's quality of life. These patients generally have neuropsychological impairments that lower their educational and occupational levels of achievement, and many have additional emotional and/or behavioral disorders. Multiple factors underlie the cognitive changes associated with epilepsy, including the effect of antiepileptic drug (AED) therapy itself. Although it is recognized that the beneficial results of reduced seizure frequency may compensate at least in part for detrimental cognitive AED side effects, polypharmacy and higher AED blood levels can shift this balance. Further, there is much debate concerning the existence and clinical importance of differential AED cognitive side effects. While all the. major AEDs can produce cognitive side effects, more recent research indicates that the magnitude of these effects may not be clinically significant with monotherapy within standard therapeutic range. The impact of AED differential cognitive side effects on the patient's quality of life is only beginning to be appreciated as research focuses on this important aspect of patient management. The information gained from such investigations will influence not only current therapeutic decisions, but also the development of future anticonvulsants.
ISSN:0362-5664
出版商:OVID
年代:1993
数据来源: OVID
|
2. |
ReviewLow- Versus High‐Dose Aspirin in Prevention of Ischemic Stroke |
|
Clinical Neuropharmacology,
Volume 16,
Issue 6,
1993,
Page 485-500
Harold Adams,
Birgitte Bendixen,
Preview
|
PDF (1059KB)
|
|
摘要:
Summary: Aspirin is the most extensively studied drug for the prevention of ischemic vascular disease. Meta-analyses confirm that aspirin is effective in prevention of ischemic events, including stroke. Recently, there has been considerable discussion about the best dose of aspirin to prevent stroke. Several studies tested aspirin in a daily dose of 975 mg or more alone or in combination with another drug, most commonly dipyridamole, and noted that aspirin was effective. Successively lower doses of aspirin were tested and recent studies demonstrate that low doses (< 100 mg/day) are effective. Only one study, enrolling patients with transient ischemic attack or minor stroke, has examined aspirin in a daily dose of ~325 mg. Side effects of aspirin are dose related; gastrointestinal bleeding and epigastric pain are less with low doses. Available data cannot confirm that low doses (< 100 mg/day) of aspirin are either more or less effective than larger (975 mg/day) doses. A direct comparison of the usefulness of low doses (< 100 mg/day) or large doses (~1,000 mg/day) in patients at high risk of stroke is needed. Until the results of such a study are known, the better safety profile of low doses favors aspirin in a daily dose of 100 mg or less.
ISSN:0362-5664
出版商:OVID
年代:1993
数据来源: OVID
|
3. |
Effects of Fasudil Hydrochloride on Cerebral Blood Flow in Patients with Chronic Cerebral Infarction |
|
Clinical Neuropharmacology,
Volume 16,
Issue 6,
1993,
Page 501-510
Ken Nagata,
Yasushi Kondoh,
Yuichi Satoh,
Yasuhito Watahiki,
Eriko Yokoyama,
Hiromichi Yuya,
Yutaka Hirata,
Fumio Shishido,
Jun Hatazawa,
Iwao Kanno,
Takanori Sone,
Preview
|
PDF (494KB)
|
|
摘要:
Summary: To evaluate the effect of the novel intracellular calcium antagonist fasudil hydrochloride, cerebral blood flow (CBF) was measured quantitatively with positron emission tomography following the intravenous administration of fasudil in five patients with chronic cerebral infarction. The hemispheric mean CBF increased significantly on both hemispheres 30, 60, and 90 min after the administration of fasudil when the CBF values were corrected according to Paco2 level, although there was no significant change in raw CBF data. A significant increase of CBF was seen in the cerebellar hemisphere and thalamus at 30 min and in the occipital cortex at 90 min. There was no significant fall in the systemic blood pressure after the administration of fasudil.
ISSN:0362-5664
出版商:OVID
年代:1993
数据来源: OVID
|
4. |
Intranasal Versus Intravenous Neostigmine in Myasthenia GravisAssessment by Computer Analysis of Saccadic Eye Movements |
|
Clinical Neuropharmacology,
Volume 16,
Issue 6,
1993,
Page 511-514
A. Costanzo,
A. Toriello,
C. Mannara,
C. Benvenuti,
G. Tedeschi,
Preview
|
PDF (347KB)
|
|
摘要:
Summary: Intranasal (i.n.) neostigmine has been developed to obtain a quicker onset of action and a more adaptable dosage regimen than oral neostigmine. The effect of this neostigmine formulation in myasthenia gravis (MG) was studied by means of computer analysis of saccadic eye movements (SEMs). Six MG patients were selected on the basis of a positive effect of Tensilon on hypometria of the first saccade. The effect of the i.v. formulation (0.5 mg) was compared to 1, 2, 3, and 4 puffs of i.n. neostigmine (one puff = 4.6 mg). The drug effect on SEMs was monitored at intervals up to 2 h. Administration of i.v. neostigmine produced a marked effect immediately after the injection and the benefit lasted over 1 h. Following administration of i.n. neostigmine a marked effect was found for two, three, and four puffs. The drug effect was evident within 3 min, peaked at 18–33 min, and lasted over 2 h. Our data indicate the efficacy of the new formulation of neostigmine in MG as measured by means of quantitative analysis of SEMs.
ISSN:0362-5664
出版商:OVID
年代:1993
数据来源: OVID
|
5. |
Famotidine Adjunctive Pharmacotherapy for SchizophreniaPreliminary Data |
|
Clinical Neuropharmacology,
Volume 16,
Issue 6,
1993,
Page 515-524
Stephen Deutsch,
Richard Rosse,
Kathleen Kendrick,
Maureen Fay-McCarthy,
Joseph Collins,
Richard Wyatt,
Preview
|
PDF (446KB)
|
|
摘要:
Summary: The usefulness of the histamine-2 (H2) antagonist famotidine as an adjunct to conventional antipsychotic treatments of idiopathic psychotic disorders (i.e., schizophrenia and schizoaffective disorder) was investigated in an open-label study. After stabilization for at least 1 week with their conventional antipsychotic medication regimen, 10 patients completed a 3-week study period in which famotidine (20 mg twice a day) was added as an adjunctive medication. The 10 patients were all somewhat treatment refractory and had spent a mean of 230 days of the previous 2 years in the hospital. Total Brief Psychiatric Rating Scale (BPRS) and Clinical Global Impression scores were significantly lower during the 3 weeks with famotidine compared with the week before and after its administration. Nevertheless, review of the scores revealed that the magnitude of the changes were small. Negative symptoms as measured by the Schedule for the Assessment of Negative Symptoms (SANS) were not significantly different during famotidine treatment, although there was the tendency for total SANS scores to be lower during famotidine treatment. When BPRS items were divided into specific versus nonspecific symptom subscales, only the specific-item subscales had significantly improved during famotidine treatment. The results of this study suggest that famotidine might prove a useful adjunctive agent in certain patients with schizophrenia. Future studies using a double-blind placebo-controlled design and higher doses are needed. Additionally, other H2 receptor antagonists with better penetration across the blood-brain barrier should be pursued.
ISSN:0362-5664
出版商:OVID
年代:1993
数据来源: OVID
|
6. |
Regional Differences in Rat Brain Dopamine Transporter BindingFunction of Time After Chronic Cocaine |
|
Clinical Neuropharmacology,
Volume 16,
Issue 6,
1993,
Page 525-539
Ana Hitri,
Richard Wyatt,
Preview
|
PDF (904KB)
|
|
摘要:
Summary: Chronic administration of cocaine to rats has been shown to produce a persistent decrease in dopamine (DA) and its metabolites in the brain and periphery. To further explore the alterations in the DA system following repeated administration of cocaine, we studied the regional differences in DA transporter binding as a function of time after the last injection of cocaine. Two groups of rats were treated with cocaine (10 mg/kg twice a day) or saline for 7 days. Rats were sacrificed 1, 2, 3, 6, and 12 weeks after the last injection. The corpus striatum and the frontal cortex were dissected and assayed with [3H]GBR 12935 for DA transporter binding. Time-related differences were observed in the frontal cortex but not in the striatum of the saline-treated control rats. Cocaine treatment prevented the time-dependent increase in Bmax over the course of 6 weeks, but not over the course of 12 weeks following withdrawal. Although there was no difference between the cocaine- and saline-treated group in the striatum at any of the time points, cocaine in the frontal cortex produced a 33% reduction in Bmax during weeks 2 and 3 and a 57% reduction in Bmax at week 6 of withdrawal; the reduction persisted for ± 12 weeks. The KD was not affected by cocaine or time in either brain region. These findings may be functionally related to cocaine craving because the DA transporter has been identified as the neuronal structure and the medial pre-frontal cortex as the anatomical site mediating cocaine reinforcement.
ISSN:0362-5664
出版商:OVID
年代:1993
数据来源: OVID
|
7. |
Brief ReportEffect of Phosphatidylcholine on Explicit Memory |
|
Clinical Neuropharmacology,
Volume 16,
Issue 6,
1993,
Page 540-549
Sandra Ladd,
Susan Sommer,
Stephen LaBerge,
William Toscano,
Preview
|
PDF (569KB)
|
|
摘要:
Summary: Previous studies have not demonstrated a consistent relationship between precursors to acetylcholine (ACh) and memory function in normal human subjects. This experiment (N = 80, college students) employed a double-blind mixed design to test the effect of phosphatidylcholine (PCh) on explicit memory. Dose of placebo and PCh was compared at two levels (10 and 25 g) as was time of testing postingestion (60 and 90 min). With 25 g of PCh, which supplies 3.75 g of choline, significant improvement in explicit memory, as measured by a serial learning task, was observed at 90 min postingestion and slight improvement was observed at 60 min postingestion. Further analyses indicated that this improvement may have been due to the responses of slow learners. This is the first study to test the relationship between a single dose of PCh and explicit memory on normal human subjects.
ISSN:0362-5664
出版商:OVID
年代:1993
数据来源: OVID
|
8. |
Brief ReportPreclamol and Parkinsonian Fluctuations |
|
Clinical Neuropharmacology,
Volume 16,
Issue 6,
1993,
Page 550-554
Zvezdan Pirtosek,
Marcelo Merello,
Arvid Carlsson,
Gerald Stern,
Preview
|
PDF (255KB)
|
|
摘要:
Summary: Preclamol, the (-)enantiomer of 3-PPP ( = 3(3-hydroxyphenyl)-7V-n-propyl piperidine), has a selective dopamine autoreceptor- and postsynaptic mixed agonist-antagonist profile. Its action on patients with disabling on-off parkinsonian fluctuations has been studied and compared with those of placebo and subcutaneous apomorphine. Preclamol had a mild but unequivocal anti-akinetic effect, less than that caused by subcutaneous apomorphine, but it provoked less dyskinesia. Further studies to explore the therapeutic potential of preclamol seem justified.
ISSN:0362-5664
出版商:OVID
年代:1993
数据来源: OVID
|
9. |
Brief ReportSumatriptan Does Not Affect Vasopressin Secretion in Humans |
|
Clinical Neuropharmacology,
Volume 16,
Issue 6,
1993,
Page 555-558
T. Barreca,
R. Franceschini,
A. Cataldi,
A. Garibaldi,
P. Cianciosi,
E. Rolandi,
Preview
|
PDF (210KB)
|
|
摘要:
Summary: The aim of the study was to investigate the effects of a new sero-toninergic drug, sumatriptan, on arginine vasopressin secretion in humans. Plasma vasopressin concentrations were determined in eight healthy volunteers, before and after administration of 6 mg of sumatriptan, or placebo. No changes in hormone levels were found after sumatriptan or placebo administration. The results suggest that in humans serotoninergic mechanisms, which modulate vasopressin secretion, do not involve the serotonin receptor activated by sumatriptan.
ISSN:0362-5664
出版商:OVID
年代:1993
数据来源: OVID
|
10. |
Pravastatin and Lovastatin in Cerebrospinal Fluid |
|
Clinical Neuropharmacology,
Volume 16,
Issue 6,
1993,
Page 559-560
Joseph Triscari,
Jeffrey Markowitz,
Mark McGovern,
Preview
|
PDF (74KB)
|
|
ISSN:0362-5664
出版商:OVID
年代:1993
数据来源: OVID
|
|